HRD
Homologous recombination deficiency reflects impaired DNA repair capability. HRD status is used to identify patients likely to benefit from PARP inhibitor therapies.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where HRD is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Ovarian Cancer Solid Tumor · Ovary |
|
Approvals defined at the solid tumor level where HRD is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report HRD as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports HRD as part of its biomarker panel.